Chloroquine for COVID-19: rationale, facts, hopes
Open Access
- 8 May 2020
- journal article
- editorial
- Published by Springer Science and Business Media LLC in Critical Care
- Vol. 24 (1), 1-3
- https://doi.org/10.1186/s13054-020-02932-4
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitroAntiviral Research, 2020
- Treating COVID-19—Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During PandemicsJAMA, 2020
- COVID-19 infection: the perspectives on immune responsesCell Death & Differentiation, 2020
- Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trialInternational Journal of Antimicrobial Agents, 2020
- Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7)Chinese Medical Journal, 2020
- Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitroCell Discovery, 2020
- A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19Journal of Critical Care, 2020
- In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)Clinical Infectious Diseases, 2020
- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitroCell Research, 2020
- Effects of chloroquine on viral infections: an old drug against today's diseasesThe Lancet Infectious Diseases, 2003